Scott Armstrong specializes in the treatment of leukemia in children. His research focuses on the disease in children and adults.

Our experts have participated in or led the development of five of the seven drugs approved by the US Food and Drug Administration for patients with advanced kidney cancer since 2005.

Two clinical trials of targeted therapies led by Memorial Sloan-Kettering investigators show promising results against different types of sarcoma.

Scientists from Memorial Sloan-Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.

Charles Sawyers, Chair of Memorial Sloan-Kettering’s Human Oncology and Pathogenesis Program, is a recipient of the inaugural $3 million prize for groundbreaking achievements in scientific research.

Researchers at Memorial Sloan-Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.

When new cancer drugs are shown to be largely ineffective, exceptional cases of good outcome may pave the way for new treatments that could benefit a smaller group of patients.